Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Shrimanker

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 2, 2017
Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future OutlookRahul Shrimanker, Ian D Pavord
Immunology and Allergy Clinics of North America|July 13, 2016
Emerging Biologics in Severe AsthmaIan D Pavord, Bart Hilvering, Rahul Shrimanker
Clinical Science (London, England : 1979)|May 11, 2017
A new approach to the classification and management of airways diseases: identification of treatable traitsRahul Shrimanker, Xue Ning Choo, Ian D Pavord
BMJ Case Reports|December 15, 2025
Congenital vascular abnormality presenting as life-long asthmaKrishan Ragab Bansal, Emma Buckroyd, William Cooper, et al.
ERJ Open Research|July 30, 2024
Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placeboImran Howell, Daniel J Bratton, Gareth Hynes, et al.
JMIR Formative Research|August 18, 2025
Comparing Approaches to Teaching Patients How to Use an App-Based Home Spirometer: Randomized Controlled TrialCaitlin Morgan, Daniel Higbee, Catherine Dixon, et al.
Mucosal Immunology|March 17, 2024
IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthmaJian Luo, Wentao Chen, Wei Liu, et al.
The Lancet. Respiratory Medicine|May 10, 2021
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational studyP Jane McDowell, Sarah Diver, Freda Yang, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 21, 2022
Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE)Freda Yang, John Busby, Liam G Heaney, et al.
Thorax|July 8, 2022
Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testingSimon Couillard, Rahul Shrimanker, Samuel Lemaire-Paquette, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 2, 2017
Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future OutlookRahul Shrimanker, Ian D Pavord
Immunology and Allergy Clinics of North America|July 13, 2016
Emerging Biologics in Severe AsthmaIan D Pavord, Bart Hilvering, Rahul Shrimanker
Clinical Science (London, England : 1979)|May 11, 2017
A new approach to the classification and management of airways diseases: identification of treatable traitsRahul Shrimanker, Xue Ning Choo, Ian D Pavord
BMJ Case Reports|December 15, 2025
Congenital vascular abnormality presenting as life-long asthmaKrishan Ragab Bansal, Emma Buckroyd, William Cooper, et al.
ERJ Open Research|July 30, 2024
Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placeboImran Howell, Daniel J Bratton, Gareth Hynes, et al.
JMIR Formative Research|August 18, 2025
Comparing Approaches to Teaching Patients How to Use an App-Based Home Spirometer: Randomized Controlled TrialCaitlin Morgan, Daniel Higbee, Catherine Dixon, et al.
Mucosal Immunology|March 17, 2024
IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthmaJian Luo, Wentao Chen, Wei Liu, et al.
The Lancet. Respiratory Medicine|May 10, 2021
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational studyP Jane McDowell, Sarah Diver, Freda Yang, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 21, 2022
Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE)Freda Yang, John Busby, Liam G Heaney, et al.
Thorax|July 8, 2022
Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testingSimon Couillard, Rahul Shrimanker, Samuel Lemaire-Paquette, et al.
Pageof 2